| Diabetes Mellitus, Non-Insulin-Dependent
Ozempic vs Steglatro
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.Deep comparison between: Ozempic vs Steglatro with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSteglatro has a higher rate of injection site reactions vs Ozempic based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Steglatro but not Ozempic, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Ozempic
Steglatro
At A Glance
SC injection
Once weekly
GLP-1 receptor agonist
Oral
Daily
SGLT2 inhibitor
Indications
- Diabetes Mellitus, Non-Insulin-Dependent
- Chronic Kidney Diseases
- Diabetes Mellitus, Non-Insulin-Dependent
Dosing
Diabetes Mellitus, Non-Insulin-Dependent Start 0.25 mg SC once weekly for 4 weeks, increase to 0.5 mg once weekly; escalate to 1 mg then 2 mg based on glycemic control (max 2 mg once weekly).
Chronic Kidney Diseases Start 0.25 mg SC once weekly for 4 weeks, increase to 0.5 mg once weekly; maintenance dose is 1 mg once weekly.
Diabetes Mellitus, Non-Insulin-Dependent Starting dose 5 mg orally once daily in the morning, with or without food; may increase to 15 mg once daily for additional glycemic control; not recommended when eGFR < 45 mL/min/1.73 m2; withhold at least 4 days prior to surgery or procedures associated with prolonged fasting.
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC) or MEN 2
- Serious hypersensitivity reaction to semaglutide or any excipient in Ozempic
- Hypersensitivity to ertugliflozin or any excipient in STEGLATRO (reactions including angioedema have occurred)
Adverse Reactions
Most common (>=5%) Nausea, vomiting, diarrhea, abdominal pain, constipation
Serious Risk of thyroid C-cell tumors, acute pancreatitis, diabetic retinopathy complications, hypoglycemia with insulin secretagogues or insulin, acute kidney injury, severe gastrointestinal reactions, hypersensitivity reactions, acute gallbladder disease, pulmonary aspiration
Postmarketing Ileus, intestinal obstruction, severe constipation, fecal impaction, anaphylaxis, angioedema, rash, urticaria, cholecystitis, cholecystectomy, dysesthesia, headache, pulmonary aspiration, acute kidney injury, alopecia
Most common (>=2%) Female genital mycotic infections, male genital mycotic infections, urinary tract infections, headache, vaginal pruritus, increased urination, nasopharyngitis, back pain, weight decreased, thirst
Serious Diabetic ketoacidosis in type 1 diabetes, lower limb amputation, volume depletion, urosepsis and pyelonephritis, hypoglycemia with insulin or insulin secretagogues, necrotizing fasciitis of the perineum (Fournier's Gangrene), genital mycotic infections
Postmarketing Necrotizing fasciitis of the perineum (Fournier's Gangrene), angioedema, rash
Pharmacology
Semaglutide is a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, stimulating insulin secretion and lowering glucagon secretion in a glucose-dependent manner, with a minor delay in gastric emptying; prolonged half-life is achieved through albumin binding, which reduces renal clearance and protects against metabolic degradation.
SGLT2 inhibitor; ertugliflozin inhibits SGLT2, the predominant transporter responsible for renal reabsorption of filtered glucose, thereby lowering the renal threshold for glucose and increasing urinary glucose excretion.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Ozempic
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
Steglatro
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Ozempic
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (0/8)
Steglatro
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (1/8) · Qty limit (1/8)
Humana
Ozempic
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Steglatro
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$25/momo
Ozempic Savings Program - Covered benefitCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Final cost depends on formulary coverage
No savings programs available for Steglatro.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
OzempicView full Ozempic profile
SteglatroView full Steglatro profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.